Stragen Healthcare Group子公司Alaxia加入欧盟的抗药性肺部感染联盟iABC项目，该联盟的合作伙伴关系将加速Alaxia开发用于治疗囊性纤维化的抗菌疗法
 
法国里昂，2019年10月23日-Stragen Healthcare Group开发呼吸系统疾病治疗解决方案的子公司Alaxia今天宣布已加入欧盟的iABC（inhaled  Antibiotics  in  Bronchiectasis  and  Cystic  Fibrosis，针对支气管扩张和囊性纤维化的吸入式抗生素）联盟。 iABC项目由来自八个欧洲国家的22个合作伙伴组成，旨在促进开发用于囊性纤维化和支气管扩张的两种吸入式抗菌剂。 这些患者特别容易患有耐药菌引起的呼吸道感染，影响患者预期寿命。
 
Alaxia joins EU consortium to combat drug-resistant lung infections
 
Partnership in iABC  project will accelerate Alaxia’s development of promising antimicrobial therapy for  cystic fibrosis
 
Lyon,  France, October 23,  2019  – Alaxia, an affiliate of the Stragen Healthcare Group developing therapeutic solutions for respiratory diseases, today announces it has joined the  iABC  (inhaled  Antibiotics  in  Bronchiectasis  and  Cystic  Fibrosis)  consortium  as  a partner. The iABC project, consisting of 22 partners in eight European countries, aims to advance  the  development  of  two  inhaled  antimicrobials  for  patients  with  cystic  fibrosis and   bronchiectasis.   These   patients   are   at   particular   risk   of   respiratory   infections, frequently caused by drug-resistant microbes that reduce life expectancy.
 
Through the consortium, Alaxia will accelerate development of its antibacterial candidate for  cystic  fibrosis,  ALX-009.  Alaxia  will  gain  access  to  all  patient  and  clinical  trial networks. It will also have access to expertise on inhaled antimicrobials from iABC members, as well as member support in clinical trials and patient recruitment.
 
“Alaxia is honored to have been selected to join the iABC project on fighting antimicrobial resistance in patients with lung diseases,” said Philippe Bordeau, VP Innovation and Business Development at Alaxia. “Our ALX-009 candidate has demonstrated strong potential  as  a  therapy  against  antibiotic  resistant  lung  infections  in  cystic  fibrosis.  We look forward to collaborating with iABC members on advancing this drug candidate and discussing this therapeutic opportunity with new financial partners.”
 
ALX-009 therapy exhibits a new multi-target mode of action that is particularly effective against antibiotic resistant strains and has shown no signs of developing additional resistance.  Antimicrobial  resistance  represents  a  serious  and  growing  threat  to  human and animal health worldwide. In the EU alone, antimicrobial resistance is responsible for approximately  25,000 deaths every year.
 
ALX-009 targets antibiotic-multi-resistant Gram-negative bacteria (‘super bugs’) that are currently untreatable. It combines two endogenous substances: the Hypothiocyanite ion (OSCN-) and the protein Lactoferrin. Both compounds are normally present in healthy people, as part of the body’s first line of defense against microbes: the innate immune system.
 
In vitro and ex vivo experiments of ALX-009 have demonstrated the 100% susceptibility of gram-negative multi-drug resistant cystic fibrosis isolates; including Burkholderia cepacia complex and other Burkholderia species, multi-drug resistant Pseudomonas aeruginosa, Achromobacter xylosoxidans and Stenotrophomonas maltophilia. These bacteria are not targeted by current therapies and may induce a rapid decline in the respiratory capacity, health status and survival of patients.
 
The lungs of  cystic fibrosis and bronchiectasis patients have large amounts of a sticky mucus (sputum). In this environment, bacteria adopt a multicellular behavior (biofilms) that facilitates survival. Both sputum and biofilms are complex molecular matrices that reduce the efficacy of current antibiotics; to restore their efficacy, a considerable dose increase is needed. In contrast to available antibiotics, ALX-009 activity is not altered by biofilms  or  sputum;  no  significant  dose  increase  is  required  to  maintain  its  infection killing efficacy.
 
ALX-009 can be used as a standalone therapy and/or as an adjunctive to antibiotics. It is in the final stages of Phase 1 in cystic fibrosis and bronchiectasis trials. Patient enrolment in Phase 2a trials is planned to start in 2020.
 
Alaxia will participate in the North American Cystic Fibrosis Conference (NACFC), October 31 - November 2, 2019, in Nashville, TN.
 
About Alaxia
Alaxia, an affiliate of the Stragen Pharma Group, specializes in developing antimicrobial therapies  for  cystic  fibrosis  and  other  chronic  respiratory  diseases.  Its  lead  product, ALX 009, a first-in-class orphan drug candidate, consists of two endogenous microbiocide substances that provide innate immunity defense within healthy lungs. Currently in the final stages of its Phase 1 trial, ALX 009 aims at treating cystic fibrosis and bronchiectasis infections against multi-drug resistant Gram-negative bacteria.
 
Alaxia is backed by the French public bank Bpifrance and the Cystic Fibrosis Foundation, with support from Stragen and now by the iABC consortium. The iABC consortium is a project  within  the  ND4BB  program  under  the  IMI  (Innovative  Medicines  Initiative),  a Public Private Partnership between the European Union and the European pharmaceutical industry.
 
Founded in 2008 in Lyon, France, the ALX-009 program is led by Dr. Victor Juarez Perez, project  leader  and  Annie  Claude  Benichou  M.D,  chief  medical  officer,  with  over  20 Stragen staff.
 
www.alaxia-pharma.eu
Media contacts
Andrew Lloyd & Associates
Jo Reeder / Juliette Schmitt-dos Santos jo@ala.com /  juliette@ala.com
Tel: +44 1273 675 100
@ALA_Group